approach end took anoth look model ep rais
nickel year unchang revenu lower slightli fx reiter outperform
pt
beat rais ep estim
still within compani guidanc rang vs consensu
revenu forecast lower fx line item adjust
modestli ep estim unchang compound-annual-growth-rate remain
intact
revenu lower slightli fx modest adjust year thereaft
lower revenu estim reflect
neg currenc impact forecast line guidanc
vs consensu product apoquel cyopoint simparica
report strong growth help support ex-fx growth approxim
rais revenu estim respect
year unchang
african swine fever asf modest near term overhang anim health
compani impact asf zoeti estim full
year impact project zoeti expect off-set loss revenu
sale market suppli increas protein demand
pork altern expect rise pleas join us thursday june et
webinar african swine fever protein predica lanc zimmerman
cattlefax information/analysi provid beef agricultur industri
topic includ quantif asf impact global suppli demand import/
export trend china impact protein rise pork price current
trade situat influenc asf supply/demand dynam comparison asf pedv
break-out call co-host cowen restaur andrew charl chemic
charli neivert pharma/anim kathi miner analyst dial-in inform
pleas contact cowen salesperson
pleas see page report import disclosur
rate share outperform base rel attract anim health
market solid outlook top- bottom-lin growth versu market
upsid possibl believ execut prospect move share higher
apoquel cytopoint sale trend
sale compound-annual-growth-rate
ep compound-annual-growth-rate
apoquel cytopoint simparica tripl
uptak greater expect
signific product emerg
restructur provid greater
apoquel cytopoint simparica tripl
new oper restructur
influx small new competitor dampen
zoeti inc engag discoveri develop manufactur commerci
anim health medicin vaccin focu livestock companion anim
primari livestock speci cattl beef dairi swine poultri sheep fish
primari companion anim speci dog cat hors zoeti spun
cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg /human ww lc ex total dog mfg /human revenu cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock cattl beef dairi swine poultri apoquel cytopoint simparica dx new product drive growthtot ahead market growth revenu driven demand protein especi em livestock lc ex pharmaq farm fish ad companion new product expand pet care dx companion lc ex -restructur lc ex revenu line market growth speci cer new product key apoquel cytopoint simparica contract mfg /human tie former contract abaxi human dx ad aug ww lc ex strong em demand safe protein beef dairi solid demand asf impact on-going steadi demand trend toward antibiotic-fre farm fish ad pharmaq sheep othertot speci trend vari geographicallycompanion total dog new product abaxi line extens drive growth nich markettot could even faster given potenti influx new drugscontract mfg /human activ pursuedtot revenu steadi gain upsid possibl cowen
compani data cowen compani
ceftiofur rev market sinc draxxin rev market sinc anti-infect sku reduct exclud growth promot livestock fish companion anim product parasiticid revolut price/or competit mainli felin use nich dog simparica oral flea tick launch eu topic felin trio review parasiticid mostli livestock fishparasiticid boost pharmaq ionophor grow off-set ractopamin shared-us anti-bio declinesoth product apoquel atop dermat dog expand acute/season use cytopoint canin atop dermat inject total pharma rimadyl sileo surgic med nexvet mab pharma undisclos pipelin product could boost genet test iv fluid embrex devic anim hlth companion anim dx abaxi close product assum small bolt-on acquisitionscontract product suppli agreementstot fx estim cowen
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog cowen
compani data cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio discount cash flow
competit dynam global potenti regulatori delay reject failur
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk price includ abil re-suppli apoquel success pipelin
product weather/diseas risk busi success independ compani
